Physician profile
Wayne M Cannon
NPI 1801861836
$7,131.54
in general payments reported to CMS, 2019-2025
26 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $135 · 2021: $736 · 2022: $1,274 · 2023: $941 · 2024: $1,428 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,101.74 | 2020-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $858.71 | 2019-2025 | Total30, Tryptyr |
| Bausch & Lomb Americas INC. | $843.40 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $522.65 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Sight Sciences, INC. | $375.95 | 2022-2025 | Omni Surgical System, Tearcare System |
| Abbvie INC. | $372.07 | 2022-2024 | Vuity |
| Allergan, INC. | $345.29 | 2019-2021 | |
| Oyster Point Pharma, INC. | $341.96 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $300.88 | 2022-2025 | |
| Horizon Therapeutics Plc | $249.79 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $242.42 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $205.30 | 2019-2021 | |
| Optos, INC. | $202.15 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $139.55 | 2019-2023 | Acuvue |
| Glaukos Corporation | $135.23 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $126.33 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $124.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $118.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $112.09 | 2024 | Acthar |
| Lkc Technologies, INC. | $97.65 | 2025 | |
| Alcon Research LLC | $85.38 | 2019 | |
| Rxsight INC | $78.95 | 2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $57.28 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $48.11 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $26.59 | 2022 | |
| Thea Pharma INC. | $19.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.